13 min.
What are the recommendations for treatment of relapsed CLL patients?
Prof. John Seymour, MD, hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia, talks about BCL2-inhibitors and MRD in relapsed/refractory disease.
Talha Munir, MD, PhD, hematologist at St James’s Hospital in Leeds (UK), explains about the role of MRD in determining the duration of therapy.